Abstract. An accurate investigation of the HER2 protooncogene is extremely important for the therapy and prognostication of breast cancer. Currently, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are standard methods for this purpose. The aim of this study was to detect the expression and amplification of HER2 in paraffin-embedded samples of breast cancer tissue and to investigate the relationship between HER2 amplification and various clinicopathological parameters in advanced breast cancers. We used FISH to examine the HER2 gene amplification and IHC to examine the expression of HER2 protein, estrogen receptor (ER) and progesterone receptor (PR) in 62 advanced breast cancers. HER2 gene amplification was detected by FISH in 12 breast cancers (19%) and HER2 protein expression with a score of 3 + was detected by IHC in 11 (17%). There was a significant correlation between the HER2 gene amplification and HER2 protein overexpression in breast cancers (P<0.0001). However, some mismatching was evident: 3 cases, negative for the HER2 gene, showed a HER2 protein expression score of 3 + and 2 cases, positive for HER2 gene amplification, had HER2 protein expression scores of 0 and 1 + (negative), respectively. ER and PR were expressed in 41 (66%) and 46 (74%) cancers, respectively. No correlation was observed between the HER2 gene amplification and any of the clinicopathological parameters examined, including age, histopathological type, TNM stage, tumor size, lymph node status, relapse and expression of PR. We observed three patterns among the 6 deceased cases: i) triple negativity for HER2, ER and PR, ii) positivity for HER2 gene amplification with a mismatching HER2 protein expression, and iii) positivity for the HER2 gene amplification with a matching HER2 protein expression score of 2 + or 3 + . The triple negative cases and HER2 gene amplification positive cases with a mismatching HER2 protein expression had a poor outcome. These results suggest that in breast cancer, the detection of HER2 gene amplification by FISH is desirable compared with the HER2 protein expression determined by IHC. Moreover, triple negativity for HER2, ER and PR is a potentially very important prognostic marker.
Introduction
HER2 is a proto-oncogene located at 17q12-21.32. The encoded product is a transmembrane 185-kDa protein with tyrosine kinase activity that belongs to the type I epidermal growth factor receptor family (1) and is known to be involved in signal transduction during cell growth (2, 3) . The amplification of the gene and concomitant overexpression of the HER2 protein has been identified in 10-34% of breast carcinomas and is considered to be not only an important biological marker of poor prognosis but also a useful indicator of response to chemotherapy or endocrine therapy (2, 4) . The development of the new anticancer drug trastuzumab, which is a recombinant humanized monoclonal antibody against the extracellular portion of the HER2 protein, and the encouraging results obtained from the treatment of patients whose breast carcinomas demonstrated HER2 amplification and/or overexpression have led to a renewed interest in HER2. Therefore, laboratory assessment of HER2 gene status has become a basic procedure for the appropriate management of breast cancer patients (5) .
Currently, the HER2 status is examined using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) which are recommended by national and international guidelines (6) . IHC has been used mainly in pathology laboratories in a routine setting for the detection of HER2 overexpression in archival material from breast carcinomas. However, the results of IHC are affected by technical factors (6) (7) (8) .
The purpose of this study was to evaluate the HER2 gene status in relation to chromosome 17 polysomy using the FISH technique as compared with the results of IHC and to evaluate the expression of ER and PR in 62 advanced breast cancers.
Materials and methods
Tissue specimens. We examined a total of 120 cases of breast cancer, including 62 cases of invasive ductal carcinoma exceeding stage II according to the 1997 WHO classification (7th edition), in patients aged 24-85 who underwent surgery at the University of Tokyo Hospital between July 2001 and June 2002. The surgical tissue samples were frozen rapidly in liquid nitrogen and stored at -80˚C until fixation. They were then fixed in 10% buffered formalin solution and embedded in paraffin. All samples were collected after obtaining informed consent from the patients and the study protocol was approved by the Medical Department of the University of Tokyo ethics committee. The pathological diagnoses were made by specialists in surgical pathology at our institution by examining the hematoxylin-eosin stained slides. All breast tumors were reviewed pathologically on the basis of the BRE score. pT and pN staging was performed according to the 1997 WHO classification (7th edition). (FISH) . FISH was performed using the PathVysion assay kit (Vysis, Inc., Downers Grove, IL), which involves direct labeling with two DNA probes: a locus-specific probe for the HER2 gene labeled with SpectrumOrange (LSI Her-2/neu) and an α satellite probe targeting the centromere region of chromosome 17 labeled with SpectrumGreen (CEP 17). The assay was performed according to the manufacturer's instructions. In brief, after deparaffinization, specimens were incubated in pretreatment solution (80˚C for 10 min) and then digested with protease (37˚C for 15 min). The LSI Her2/CEP 17 probe was applied, the slide was sealed with a coverslip and the specimen was hybridized overnight at 37˚C. The slides were then washed, counterstained with DAPI and viewed by fluorescence microscopy. In each breast cancer specimen an average of 60 nuclei was enumerated in the invasive part of the tumor. The HER2 gene copy number, chromosome 17 copy number and the average HER2 gene to chromosome 17 signal ratio were evaluated as FISH genetic variables. Samples with a ratio value of >2.0 were considered to be amplified.
Fluorescence in situ hybridization

Immunohistochemistry (IHC).
The expression of the HER2 protein was determined in 5-μm paraffin sections by two-step immunohistochemical staining using a commercial kit (HERcep Test, Dako, Glostrup, Denmark) according to the manufacturer's instructions. After incubation with the primary rabbit antibody against the human HER2 protein, a secondary goat anti-rabbit immunoglobulin conjugated with horseradish peroxidase was applied for visualization. Slides immunostained for ER and PR were scored as previously described (9, 10) . Each entire slide was evaluated by light microscopy. First, a proportional score was assigned, representing the estimated proportion of positively-stained tumor cells (0, none; 1, <1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3 and 5, >2/3). Then an intensity score was assigned, representing the average intensity of positive staining (0, none; 1, weak; 2, intermediate and 3, strong). The proportion and intensity scores were then added to obtain a total score, which ranged from 0 to 8. Slides were scored by pathologists who were blinded to ligand-binding results or patient outcome. Nuclear signals for the ER (Fig. 3A) and PR (Fig. 3B) , as assessed by IHC, were observed in 41 (66%) and 46 (74%), respectively, of the 62 breast cancers with positivity scores ranging from 2 to 8 (Table I) . No correlation was observed between the HER2 gene amplification and any of the clinicopathological parameters, including age, histopathological type, TNM stage, tumor size, lymph node status and the expression of PR. However, there was a significant correlation between HER2 gene amplification and ER expression (P=0.0148) ( Table I) .
We also investigated the relationship of HER2 gene amplification and protein overexpression with the clinicopathological parameters in 6 deceased cases (Table II) . Two of these cases were triple negative [HER2 gene (-), ER (-) and PR (-)], 2 were HER2 gene positive with the HER2 protein mismatching by IHC and 2 were HER2 gene positive with a HER2 protein overexpression score of 2 + and 3 + , respectively. The 2 triple negative cases (4 and 5) had a poor outcome, and the patients survived for <30 months. The 2 cases in which HER2 gene amplification and protein overexpression matched (cases 3 and 6) were treatable with trastuzumab in the early stage of illness and the patients survived for >48 months. However, the 2 cases showing a mismatch between positive HER2 gene amplification and negative protein overexpression (cases 1 and 2) were not treatable with trastuzumab, and the patients showed a very short survival of <22 months.
Discussion
Determining the HER2 status in breast cancer is extremely important, not only in metastatic disease to determine eligibility for trastuzumab therapy but also in an adjuvant setting for the selection of appropriate chemotherapy (11) (12) (13) . For the clinical determination of the HER2 status, the US Food Table I . Characteristics of the breast cancer patients in this study.
-----------------------------------------------------------------------------------------------------
No. of patients (%) 
(27) 8 (77) -----------------------------------------------------------------------------------------------------
a χ 2 test; NS, not significant. b T4, direct invasive to chest wall and/or skin.
- (14) . In the present study, there was a significant correlation between HER2 gene amplification and HER2 protein overexpression in breast cancers (P<0.0001). Only 2 (20%) of the cases showing a HER2 protein score of 2 + by IHC demonstrated HER2 gene amplification by FISH. However, there was mismatching in 3 cases between HER2 gene negativity and positivity for HER2 protein with a score of 3 + , and in 2 cases between HER2 gene amplification and positivity for HER2 protein with scores of 0 and 1 + (negative), respectively. These results suggest that detection of the HER2 protein expression by IHC alone is not satisfactory for the evaluation of HER2 status. Although previous studies have demonstrated a significant correlation between HER2 gene amplification and the expression of hormone receptors (11) (12) (13) , in the present studies, we found a significant correlation between HER2 gene amplification and the expression of ER (P=0.0148). We are unable to explain this result, and consider that additional cases will be required to clarify this issue.
HER2 gene amplification and protein overexpression are associated with aggressive biological characteristics and poor clinical outcome in breast cancer patients. However, a consensus has not been reached regarding the value of HER2 as a valid prognostic indicator (15) (16) (17) (18) . In the present study, we investigated the relationship of HER2 gene amplification and protein overexpression with clinicopathological parameters in 6 deceased cases of breast cancer. We were able to classify these cases into three types: i) triple negativity for HER2, ER and PR, ii) positivity for the HER2 gene amplification with a mismatching of HER2 protein expression demonstrated by ONCOLOGY REPORTS 19: 651-656, 2008 Table II . Relationship of HER2 gene amplification and protein overexpression in 6 deceased cases. -
IHC, and iii) positivity for HER2 gene amplification with matched expression of HER2 protein with a score of 2 + and 3 + . The triple negative cases had a poor outcome, the cases showing matching between HER2 gene amplification and protein overexpression were treatable with trastuzumab in the early stage of illness and had a positive outcome, and the cases showing the mismatching between positive HER2 gene amplification and negative protein overexpression were not treatable with trastuzumab and had a poor outcome. In clinical practice, we tested for HER2 protein first and then examined HER2 gene amplification by FISH in cases where the HER2 protein expression score was 2 + . Occasionally, therefore, if HER2 protein overexpression is absent and gene amplification is detected later, it may be too late to start trastuzumab therapy. These results suggest that triple negative cases and cases positive for HER2 gene amplification and negative for HER2 protein overexpression have a very poor prognosis. On the other hand, trastuzumab appears to be very effective against breast cancers that are positive for HER2 gene amplification.
On the basis of the present findings, we believe that trastuzumab therapy should be started as soon as possible for cases that are positive for HER2 gene amplification. Merola et al have raised the clinically relevant question of whether patients with polysomy, IHC 2 + and FISH negativity may also benefit from trastuzumab therapy (19) and we think that further studies are required to determine clearly the types of patients who would gain most benefit from trastuzumab.
In conclusion, we believe that detection of the HER2 gene amplification by FISH compared with the HER2 protein expression by IHC is valuable in patients with breast cancer. It also appears that triple negativity for HER2, ER and PR has considerable importance as a potential prognostic indicator.
